Answers are grounded in this paper and cite their sources.
The increasing use of lenalidomide (Len) in first-line (1L) therapy of multiple myeloma (MM) has led to a significant proportion of patients becoming Len-refractory following 1L treatment. However, there are limited real-world data on treatment strategies and outcomes of patients who become Len-refractory following 1L therapy.
No takes yet. Share an insight, caveat, or question.
Kastritis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: